#United States #Class Action #San Francisco #VYKAT XR #Soleno Therapeutics

Soleno Therapeutics Faces Legal Action Amid Drug Launch Challenges

Soleno Therapeutics, Inc. (NASDAQ: SLNO) has recently come under fire as a class action lawsuit seeks to represent its investors who acquired shares during a tumultuous period. This lawsuit follows the company’s disappointing release of trial results for its new drug, VYKAT™ XR, intended to treat hyperphagia, a severe condition linked to Prader-Willi Syndrome (PWS). The launch of this medication has now led to significant legal ramifications and a sharp decline in shareholder value.

The lawsuit highlights the timeline between March 26, 2025, and November 4, 2025, focusing on allegations that Soleno misrepresented critical information regarding the safety and effectiveness of VYKAT™ XR. On November 5, 2025, after releasing disappointing findings about its drug, which the firm described as essential for patients suffering from the life-limiting aspects of PWS, the company's stock dropped by a staggering 26% in a single day. This sudden market reaction not only reflects the investor sentiment but also has raised serious questions about the reliability of Soleno's previous communications regarding the medication.

During this period, Soleno asserted that the drug launch had exceeded expectations, continuing to promote a successful trajectory. However, subsequent reports revealed troubling safety issues linked to the administration of VYKAT™ XR, including incidents of significant fluid retention in trial participants. These revelations allegedly contradicted the company's prior claims about the drug's safety and market viability. Furthermore, there were mounting concerns about adverse effects, which cast doubt upon the initial claims of a favorable commercial outlook.

The allegations intensified when activist short seller Scorpion Capital pointed to various red flags in Soleno's disclosures, suggesting that there was not only a manipulation of data but also serious oversights in clinical trial procedures. Reports surfaced regarding children's hospitalization due to potential heart failure following dosage of VYKAT™ XR, leading to concerns about the medication's future in the market. With observers questioning the integrity of the clinical trials, Soleno's management admitted during their November earnings call that the launch had experienced a disruption, attributing part of this downfall to the fallout from Scorpion’s August report.

This legal scrutiny does not only reflect a drop in confidence among investors but also opens the door for substantial financial losses for those who may have trusted the company’s assessments. As the landscape shifts, Hagens Berman, a law firm representing the plaintiffs, urges affected investors to file their claims as they investigate potential violations of federal securities laws. The firm leads an inquiry into whether Soleno provided false assurances about VYKAT™ XR’s prospects for commercialization.

As the drama unfolds, Soleno Therapeutics finds itself navigating a treacherous legal path, and the outcomes of these proceedings could have far-reaching implications for the future of both the company and its stakeholders. Investors are left in a precarious position regarding their assets while also looking for clarity on the claims made by such a prominent player in the biotech field. The case highlights the broader issues of transparency and accountability in the pharmaceutical industry, particularly when it comes to the health and safety of patients relying on these critical therapies.

In light of the developments, anyone with insights or non-public information regarding Soleno is encouraged to participate in the investigation. Whistleblowers may avail themselves of protections and benefits under the SEC Whistleblower program, paving the way for corporate accountability and possibly leading to remedial actions for affected investors.